Day: November 3, 2022

On May 31, 2014, Zhao, Hongwu; Meng, Wei; Yang, Zhao; Tian, Ting; Sheng, Zhihui; Li, Hailong; Song, Xiuqing; Zhang, Yutong; Yang, Sen; Li, Bo published an article.SDS of cas: 75449-26-2 The title of the article was Organocatalytic Stereoselective Synthesis of 3-Alkyl-3-hydroxy-2-oxindoles Catalyzed by Novel Water-compatible Axially Unfixed Biaryl-based Bifunctional Organocatalysts. And the article contained the following:

In this work, six novel axially unfixed biaryl-based water-compatible bifunctional organocatalysts were designed and synthesized for the organocatalytic access to a variety of 3-alkyl-3-hydroxy-2-oxindole derivatives I (R1 = H, 5-O2N, 5-Br; R2 = H, Bn; R3, R4 = -(CH2)2-, -CH2OCH2-, -CH2SCH2-, etc.) via aldol reactions in water. Organocatalyzed by II, the direct aldol reactions of isatins with enolisable ketones underwent readily in water, furnishing the structurally diverse I in various stereoselectivities (up to>99% dr and >99% ee). Moreover, a plausible transition state of the conducted aldol reactions was hypothesized to shed light on the observed stereoselectivities of the obtained I. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).SDS of cas: 75449-26-2

The Article related to alkyl hydroxy oxindole enantioselective preparation, isatin ketone aldol biaryl organocatalyst water compatible, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.SDS of cas: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 27, 2007, Arnold, James; Berg, Stefan; Chessari, Gianni; Congreve, Miles; Edwards, Phil; Holenz, Joerg; Kers, Annika; Kolmodin, Karin; Murray, Christopher; Patel, Sahil; Rakos, Laszlo; Rotticci, Didier; Sylvester, Mark; Oehberg, Liselotte published a patent.Computed Properties of 908267-63-0 The title of the patent was Substituted isoindoles as BACE inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cognitive impairment, Alzheimers disease, neurodegeneration and dementia. And the patent contained the following:

This invention relates to compounds having the structural formula I and to their pharmaceutically acceptable salt, compositions and methods of use. These compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer disease, neurodegeneration and dementia. Compounds of formula I wherein R1 is H, NO2, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl;, CONH-C1-6 alkyl, etc.; R2 is Me, (un)substituted C0-3 alkyl-C3-6 cycloalkyl, NO2, CN, substituted C2-4 alkenyl, etc.; R3 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, etc.; m is 0, 1, 2, and 3; and their pharmaceutically acceptable salts, solvates, salts of solvates thereof are claimed. Example compound II•TFA was prepared by Suzuki cross-coupling of [3-(3-bromo-4-hydroxyphenyl)-3-(4-methoxyphenyl)-3H-isoindol-1-yl]carbamic acid tert-Bu ester with 3-methoxyphenylboronic acid; the resulting [3-(6-hydroxy-3′-methoxybiphenyl-3-yl)-3-(4-methoxyphenyl)-3H-isoindol-1-yl]carbamic acid tert-Bu ester underwent hydrolysis to give compound II•TFA. All the invention compounds were evaluated for their BACE inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 67 nM. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Computed Properties of 908267-63-0

The Article related to substituted isoindole preparation bace inhibitor, treatment alzheimer disease neurodegeneration dementia cognitive impairment isoindole preparation, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Computed Properties of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 15, 2017, Wei, Na; Zhang, Yue; Liu, Lin; Han, Zheng-Bo; Yuan, Da-Qiang published an article.Recommanded Product: 1431292-15-7 The title of the article was Pentanuclear Yb(III) cluster-based metal-organic frameworks as heterogeneous catalysts for CO2 conversion. And the article contained the following:

Two porous metal-organic frameworks (MOFs) incorporating pentanuclear Yb(III) clusters and pyridyl-supported tetracarboxylates or pyridyl carboxylic acid-supported tetracarboxylates, Yb-DDPY and Yb-DDIA, are presented, in which the pentanuclear Yb(III) cluster shows uncommon trigonal bipyramidal geometry. Furthermore, the pentanuclear Yb(III) clusters are extended by tetracarboxylates to form a 3D porous framework with uniform M12L8-cages constructed by 12 pentanuclear Yb(III) clusters and 8 tetracarboxylates with the size of ∼20 Å × 17 Å. Their highly CO2 uptake capacity and the existence of Lewis acidic sites make these MOFs promising catalysts for the chem. conversion of CO2. These MOFs demonstrate good catalytic activities and recyclability in the cycloaddition of CO2 and epoxides at 60° under 1.0 MPa pressure or at room temperature and atm. pressure. In addition, the synergistic effect of the Bronsted acidic -COOH groups and the Lewis acidic Yb(III) sites makes Yb-DDIA exhibit higher catalytic activity towards the cycloaddition of CO2 and epoxides. The experimental process involved the reaction of 5,5′-(Pyridine-2,5-diyl)diisophthalic acid(cas: 1431292-15-7).Recommanded Product: 1431292-15-7

The Article related to pentanuclear ytterbium metal organic framework catalyst carbon dioxide cycloaddition, carbon dioxide epoxide cycloaddition catalyst cyclic carbonate, Industrial Organic Chemicals, Leather, Fats, and Waxes: Manufacture Of Industrial Organic Chemicals and other aspects.Recommanded Product: 1431292-15-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 24, 1994, Rewcastle, Gordon W.; Palmer, Brian D.; Dobrusin, Ellen M.; Fry, David W.; Kraker, Alan J.; Denny, William A. published an article.COA of Formula: C7H10N2 The title of the article was Tyrosine Kinase Inhibitors. 3. Structure-Activity Relationships for Inhibition of Protein Tyrosine Kinases by Nuclear-Substituted Derivatives of 2,2′-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide). And the article contained the following:

A series of indole-substituted 2,2′-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamides) I (R = H, 5-Cl, 6-Me, 7-OH, 5-MeO, etc.) were prepared and evaluated for their ability to inhibit the tyrosine kinase activity of both the epidermal growth factor receptor (EGFR) and the nonreceptor pp60v-src tyrosine kinase. The compounds were synthesized by conversion of appropriate 1-methyloxindoles to 1-methyl-2-indolinethiones with P2S5 followed by subsequent reaction with NaH and Ph isocyanate and oxidative dimerization of the resulting 2,3-dihydro-N-phenyl-2-thioxo-1H-indole-3-carboxamides. The parent compound and many of the substituted analogs were moderately potent inhibitors of both kinase enzymes, but no clear relationships were seen between substitution on the indole ring and inhibitory activity. While 4-substituted compounds were generally inactive, 5-substituted derivatives with electron-withdrawing groups showed inhibitory activity. However, none of the substituted compounds showed significantly better activity than the unsubstituted parent compound There was generally a good correlation between activity against the EGFR and pp60v-src kinases, but several compounds did show some specificity (>20-fold) of inhibition; 5-Cl and 5-Br derivatives preferentially inhibited pp60v-src, while the 5-CF3 compound preferentially inhibited EGFR. Selected compounds from the series were found to inhibit the growth of Swiss 3T3 fibroblasts with IC50s in the range 2-25 μM, the most active being 4-substituted derivatives The compounds inhibited bFGF-mediated protein tyrosine phosphorylation in intact cells more effectively than EGFR- or PDGF-mediated phosphorylation. The experimental process involved the reaction of N,3-Dimethylpyridin-2-amine(cas: 156267-13-9).COA of Formula: C7H10N2

The Article related to dithiobismethylphenylindolecarboxamide protein tyrosine kinases inhibitor, indolecarboxamide dithiobismethylphenyl protein tyrosine kinases inhibitor, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.COA of Formula: C7H10N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 23, 1997, Onodera, Akira; Ninomiya, Hidetaka; Ohya, Hidenobu; Ishibashi, Daisuke; Komamura, Tawara; Katoh, Katsunori; Tanaka, Tatsuo; Morimoto, Hitoshi published a patent.Computed Properties of 28489-43-2 The title of the patent was Azomethine dyes and their use in ink-jet recording inks. And the patent contained the following:

A recording method comprises the step of ejecting an ink-jet recording ink on a receptor using an ink-jet printer, the ink comprising a dye represented by the formula I [R1, R2 = H, halogen, NH2, organic group; X = OH, NR3R4; R3, R4 = H, hydrocarbyl, heterocyclyl, or R1R3 or R3R4 form a ring; Y1, Y2 = N, CR; R = H, alkyl, acylamino; Y1 or Y2 = N; Z completes an (un)substituted 5- or 6-membered ring, which may bear another condensed ring; R2 or a substituent on Z has Hammett σp -0.3 to +1.0]. Thus, II was prepared in a 9-step synthesis from 6-methyl-2-pyridinamine and 5-tert-butyl-2-hydrazino-6H-1,3,4-thiadiazine. An ink with good color tone and storage stability was prepared from a I 3, H(OCH2CH2)2OH 10, Bu(OCH2CH2)3OH 7, PrOH 3, and H2O 77%. The experimental process involved the reaction of N,N-DIethyl-6-methyl-5-nitro-2-pyridinamine(cas: 28489-43-2).Computed Properties of 28489-43-2

The Article related to azomethine dye jet printing ink, pyrazolotriazole azomethine dye, aminopyridine azomethine dye, Dyes, Organic Pigments, Fluorescent Brighteners, and Photographic Sensitizers: Azo Dyes and Pigments and other aspects.Computed Properties of 28489-43-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 30, 2021, Zhou, Enxing; Liu, Yuan; Wang, Hanping; Wang, Jing; Shao, Ning; Wu, Guanglong published a patent.Product Details of 908267-63-0 The title of the patent was Preparation of heteroaromatics and their methods for inhibiting casein kinases. And the patent contained the following:

The disclosure provides methods for inhibiting CK1 delta or CK1 epsilon activity, comprising administering an effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof. Compounds of formula I wherein Ar1 is (un)substituted aryl; X1, X2 and X3 are independently C and N; R7 is absent and CN; ring A is absent, X1:CR2 and R3X1:CR2, 4- to 7-membered cycloalkyl, heterocycloalkyl, etc.; R2 is NH2, CN, carboxy, azido, etc.; R3 is halo and CN; ring B is absent, X2CR5, R6X2CH and R6X2CR5, 4- to 7-membered cycloalkyl, etc.; R5 is CO2-C1-6 alkyl, COR10, azido, amido, etc.; R10 is 4- to 7-membered cycloalkyl, heterocycloalkyl and 5- to 6-membered heteroaryl; R6 is C1-6 alkyl, azido, amido, aryl, etc.; dashed bonds are single and double bonds; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their casein kinase inhibitory activity. From the assay, it was determined that compound II exhibited 7.9 nM towards CK1δ. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Product Details of 908267-63-0

The Article related to heteroaromatic preparation casein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 15, 2018, Chen, Xuxing; Geng, Meiyu; Jiang, Lei; Chen, Yi; Cao, Jianhua; Jiang, Qingyun; Shen, Qianqian; Ding, Jian; Yao, Yucai; Zhao, Zhao; Xiong, Yuanfang published a patent.Safety of 4-Bromo-2-isopropylpyridine The title of the patent was Pyrido five-element aromatic ring compound, preparation method therefor and use thereof. And the patent contained the following:

The present invention provides a pyrido five-element aromatic ring compound (e.g., I), and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Safety of 4-Bromo-2-isopropylpyridine

The Article related to pyridoarom ezh inhibitor antitumor autoimmune preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 4-Bromo-2-isopropylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 22, 2014, Chatterjee, Arnab Kumar; Nagle, Advait Suresh; Paraselli, Prasuna; Leong, Seh Yong; Roland, Jason Thomas; Mishra, Pranab Kumar; Yeung, Bryan K. S.; Zou, Bin published a patent.Formula: C7H10N2 The title of the patent was Preparation of imidazopyrazines for treating parasitic diseases. And the patent contained the following:

The invention is related to the preparation of title compounds I [n = 0-2; p = 0-3; A = aryl, heteroaryl, and fused bycyclyl comprising a heterocycloalkyl fused to a phenyl; B = the imidazo[1,2-a]pyrazine fused ring depicted in I; D = Ph, heteroaryl, cycloalkyl, heterocycloalkyl, fused bicyclyl comprising a heterocycloalkyl fused to a phenyl; L = *CO, alkylene, *NR2CO, *CH2NR2, etc.; * represents the point of attachment of L to ring B; R2 = H, alkyl, R0-alkylene ; R0 = alkoxyamino, heteroaryl, alkylamino, etc.; R1 = independently at each occurrence halo, CN, NH2 and derivatives; R15, R16 = independently H, alkyl, haloalkyl; R17 = independently at each occurrence halo, OH and derivatives, SO2NH2 and derivatives, etc.], or a pharmaceutical acceptable salt, tautomer or stereoisomer, useful for treating, preventing, inhibiting, ameliorating, or eradicating the pathol. and/or symptomol. of a disease, such as malaria, caused by a Plasmodium parasite. Thus, a multi-step synthesis starting from chloroacetaldehyde and 5-amino-2-pyrazinecarboxylic acid Et ester was given for II. I were tested for their capacity to inhibit proliferation of parasitemia in 3D7 Plasmodium falciparum infected red blood cells and had EC50 of 10 μM or less. I showed delay of the proliferation of P. yoelii in liver cells in a P. yoelii sporozoite invasion assay (EC50 for II = 14 nM). The experimental process involved the reaction of N,3-Dimethylpyridin-2-amine(cas: 156267-13-9).Formula: C7H10N2

The Article related to imidazopyrazine preparation antimalarial plasmodium falciparum, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C7H10N2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Safety of 3,5-Dibromo-4-methoxypyridine The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Safety of 3,5-Dibromo-4-methoxypyridine

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 7, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Application of 25813-24-5 The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Application of 25813-24-5

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem